康复新液联合奥美拉唑肠溶胶囊治疗十二指肠溃疡临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R573.1

基金项目:


Clinical Study on Kangfuxin Liquid Combined with Omeprazole Enteric-Coated Capsules for Duodenal Ulcer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察康复新液联合奥美拉唑肠溶胶囊治疗十二指肠溃疡的疗效。方法:选取94 例十二指肠 溃疡患者,按随机数字表法分为对照组及观察组各47 例。对照组予以奥美拉唑肠溶胶囊治疗,观察组予以奥 美拉唑肠溶胶囊联合康复新液治疗。比较2 组临床疗效及不良反应发生率、复发率,比较2 组治疗前后症状评 分、炎症因子[超敏C-反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)]、胃液表皮生 长因子(EGF)、生活质量量表(SF-36) 评分的变化。结果:观察组临床疗效总有效率为93.62%,对照组总 有效率为78.72%,2 组比较,差异有统计学意义(P<0.05)。治疗后,2 组腹痛、反酸及烧灼感评分均较治疗 前下降,观察组上述3 项评分均低于对照组,差异均有统计学意义(P<0.05)。治疗后,2 组hs-CRP、IL-6 及IL-8 水平均较治疗前下降(P<0.05),观察组hs-CRP、IL-6、IL-8 水平均低于对照组(P<0.05)。治疗 后,2 组EGF 水平均较治疗前升高(P<0.05),观察组EGF 水平高于对照组(P<0.05)。观察组不良反应发 生率为8.51%,对照组不良反应发生率为12.77%,2 组不良反应发生率比较,差异无统计学意义(P>0.05)。 随访6 个月,观察组复发率为9.09%,对照组复发率32.43%,2 组复发率比较,差异有统计学意义(P< 0.05)。结论:康复新液联合奥美拉唑肠溶胶囊治疗十二指肠溃疡能有效提升疗效,改善临床症状,降低炎症 因子水平,改善生活质量,减少复发,安全性较好。

    Abstract:

    Abstract: Objective: To observe the curative effect of Kangfuxin Liquid combined with Omeprazole Enteric - Coated Capsules for duodenal ulcer. Methods: A total of 94 patients with duodenal ulcer were selected and divided into the control group and the observation group according to the random number table method, with 47 cases in each group. The control group was treated with Omeprazole Enteric-Coated Capsules, and the observation group was treated with Omeprazole Enteric-Coated Capsules combined with Kangfuxin Liquid. The clinical effects, incidence of adverse reactions and recurrence rates were compared between two groups,and the changes in symptom scores,inflammatory factors [hypersensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), and interleukin-8 (IL-8)], gastric epidermal growth factor (EGF), and Quality of Life Scale (SF-36) scores were compared in the two groups before and after treatment. Results: The total effective rate was 93.62% in the observation group, and 78.72% in the control group, the difference being significant (P<0.05). After treatment, the scores of abdominal pain, acid reflux, and burning sensation in the two groups were decreased when compared with those before treatment, and the above three scores in the observation group were lower than those in the control group, differences being significant (P<0.05). After treatment, the levels of hs-CRP, IL-6, and IL-8 in the two groups were decreased when compared with those before treatment (P<0.05),and the levels of hs-CRP,IL-6 and IL-8 in the observation group were lower than those in the control group (P<0.05). After treatment, the EGF levels in the two groups were increased when compared with those before treatment (P<0.05), and the EGF level in the observation group was higher than that in the control group (P<0.05). The incidence of adverse reactions was 8.51% in the observation group, and 12.77% in the control group,there being no significance in the difference (P>0.05). After following up for 6 months, the recurrence rate was 9.09% in the observation group,and 32.43% in the control group,the difference being significant (P<0.05). Conclusion: Kangfuxin Liquid combined with Omeprazole Enteric-Coated Capsules for duodenal ulcer can effectively improve the curative effect, clinical symptoms and quality of life,reduce inflammatory factor levels and recurrence,with good safety.

    参考文献
    相似文献
    引证文献
引用本文

张建海,俞建洪.康复新液联合奥美拉唑肠溶胶囊治疗十二指肠溃疡临床研究[J].新中医,2024,56(1):67-71

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-01-16
  • 出版日期:
文章二维码